Citi upgrades Mirati Therapeutics to 'buy' with a price target of $48.00

  • Investing.com
Citi upgrades Mirati Therapeutics to 'buy' with a price target of $48.00

An analyst from Citi upgraded Mirati Therapeutics (NASDAQ: MRTX ) from 'neutral' to 'buy' with a price target of $48.00 from a prior price target of %currency%%price%.

Prior to this rating, Mirati Therapeutics had 11 buy ratings, 6 hold ratings, and 1 sell ratings.

For consensus analyst estimates and price targets on Mirati Therapeutics, click here. For more news on Mirati Therapeutics, click here.

Mirati Therapeutics's stock price closed at $37.00. They are down -1.62% in the last month and down -54.01% in the last 12 months.

According to Investing Pro, Mirati Therapeutics's fair value is $28.82, a downside of 22.09%. Mirati Therapeutics's fair value comes with a high degree of uncertainty, according to InvestingPro.

Check out Mirati Therapeutics's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles